Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-1553 and IN10018 in Advanced Solid Tumors with KRasG12C Mutation
NCT05379946Phase 2Active, not recruiting
- Sponsor
- InventisBio
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in solid tumor, sponsored by InventisBio. Started Oct 2022; status: active, not recruiting.
02
Drugs
garsorasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05379946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379946.